PLRX
Pliant Therapeutics, Inc.NASDAQHealthcare$1.35+2.27%ClosedMarket Cap: $83.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.44
P/S
0.00
EV/EBITDA
-0.44
DCF Value
$0.27
FCF Yield
-158.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-69.6%
ROA
-66.3%
ROIC
-73.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-21.1M | $-23.6M | $-0.38 | — |
| FY 2025 | $0.00 | -Infinity% | $-150.1M | $-149.3M | $-2.43 | — |
| Q3 2025 | $0.00 | NaN% | $-28.3M | $-26.3M | $-0.43 | — |
| Q2 2025 | $0.00 | -Infinity% | $-45.6M | $-43.3M | $-0.71 | — |
| Q1 2025 | $0.00 | NaN% | $-58.9M | $-56.2M | $-0.92 | — |
| Q4 2024 | $0.00 | NaN% | $-53.3M | $-49.7M | $-0.82 | — |
| FY 2024 | $0.00 | NaN% | $-228.4M | $-210.3M | $-3.47 | — |
| Q3 2024 | $0.00 | NaN% | $-62.0M | $-57.8M | $-0.95 | — |
| Q2 2024 | $0.00 | -Infinity% | $-60.6M | $-55.9M | $-0.92 | — |
| Q1 2024 | $0.00 | -Infinity% | $-52.4M | $-47.0M | $-0.78 | — |
| Q4 2023 | $0.00 | NaN% | $-47.0M | $-41.1M | $-0.69 | — |
| FY 2023 | $1.6M | 100.0% | $-184.1M | $-161.3M | $-2.75 | — |